세계의 자가면역질환 치료제 시장 예측(-2032년)

According to Stratistics MRC, the Global Autoimmune Disease Therapeutics Market is accounted for $7.1 billion in 2025 and is expected to reach $13.6 billion by 2032 growing at a CAGR of 9.6% during the forecast period. Autoimmune Disease Therapeutics refers to treatments designed to manage and alleviate conditions in which the immune system mistakenly attacks the body's own healthy tissues. These therapeutics aim to suppress abnormal immune responses, reduce inflammation, and prevent further tissue damage. They include drugs such as corticosteroids, immunosuppressants, biologics, and targeted therapies that modulate specific immune pathways. Autoimmune disease therapeutics are used to treat disorders like rheumatoid arthritis, lupus, multiple sclerosis, and inflammatory bowel disease. Ongoing research focuses on developing safer, more effective, and personalized treatments that restore immune balance without compromising the body's defense against infections.

Market Dynamics:

Driver:

Rising disease prevalence & diagnosis rates

Autoimmune conditions are increasing globally due to genetic predisposition environmental triggers and lifestyle factors. Platforms support immunomodulation symptom control and disease progression management using biologics small molecules and targeted therapies. Integration with telehealth remote monitoring and personalized medicine enhances accessibility and treatment outcomes. Demand for scalable and evidence-based solutions is rising across aging populations and high-risk cohorts. These dynamics are propelling platform deployment across autoimmune-focused care ecosystems.

Restraint:

Pricing pressure & reimbursement limits

Biologics and specialty drugs require significant investment and recurring expenses for administration monitoring and supportive care. Reimbursement gaps and fragmented payer policies further complicate access and affordability. Enterprises face challenges in aligning pricing models with clinical outcomes and patient engagement. Vendors must offer value-based contracts biosimilar options and cost-transparent platforms to improve uptake. These constraints continue to hinder platform maturity across low-income and underinsured populations.

Opportunity:

Advances in targeted biologics & small molecules

Patients increasingly prefer virtual consultations and home-based monitoring to avoid clinical wait times and improve convenience. Platforms integrate with mobile apps cloud-based analytics and wearable sensors to deliver real-time insights and personalized therapy. Demand for scalable and privacy-compliant solutions is rising across primary care employer wellness and insurance-backed programs. Vendors offer modular kits AI-driven triage and outcome dashboards to support hybrid care models.

Threat:

Competition and biosimilar entry

Many regions lack trained specialists diagnostic labs and reimbursement frameworks to support widespread screening and treatment. Cultural stigma low health literacy and limited digital access further degrade demand and engagement. Enterprises face challenges in deploying scalable and regionally adapted solutions across rural and peri-urban populations. Vendors must invest in education campaigns mobile-first platforms and public-private partnerships to expand reach.

Covid-19 Impact:

The pandemic disrupted immunology clinics diagnostic workflows and therapy adherence across global markets. Lockdowns delayed in-person visits and reduced access to specialists and infusion centers. Post-pandemic recovery emphasized remote care digital diagnostics and patient self-management across autoimmune medicine. Investment in telemonitoring AI screening and home-based therapy surged across healthcare systems and consumer channels. Public awareness of immune health and its link to infection risk and chronic disease management increased across policy and clinical circles.

The biologics segment is expected to be the largest during the forecast period

The biologics segment is expected to account for the largest market share during the forecast period due to its therapeutic relevance, innovation pipeline, and clinical efficacy across autoimmune conditions. Platforms support anti-inflammatory, immunosuppressive, and targeted interventions that complement conventional therapies. Integration with personalized medicine, biomarker tracking, and combination protocols enhances treatment outcomes and patient stratification. Demand for non-steroidal and precision-driven options is rising across chronic and refractory cases. Vendors offer monoclonal antibodies, fusion proteins, and cytokine modulators tailored to autoimmune disease profiles.

The inflammatory bowel disease segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the inflammatory bowel disease segment is predicted to witness the highest growth rate as autoimmune platforms expand across gastrointestinal and systemic inflammation management. Conditions such as Crohn's disease and ulcerative colitis are increasing due to dietary shifts, microbiome disruption, and genetic susceptibility. Platforms support symptom tracking, flare prediction, and integrated care across gastroenterology and immunology workflows. Integration with telehealth, wearable sensors, and patient-reported outcomes enhances personalization and adherence. Demand for scalable and cross-specialty solutions is rising across specialty clinics, payer networks, and public health programs.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share due to its population density, rising disease burden, and healthcare modernization across autoimmune medicine. Countries like China, India, Japan, and South Korea scale platforms across urban hospitals, employer wellness, and public health programs. Government-backed initiatives support infrastructure development, digital health adoption, and awareness campaigns across chronic disease management. Local providers offer cost-effective, culturally adapted, and mobile-first solutions tailored to regional needs. Demand for scalable and inclusive autoimmune infrastructure is rising across urban and peri-urban markets.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR as innovation, reimbursement, and clinical adoption converge across autoimmune disease technologies. Enterprises deploy platforms across homecare, telehealth, and integrated care networks to improve access and outcomes. Investment in AI diagnostics, biologics, and digital therapeutics supports scalability and personalization. Presence of leading vendors, academic institutions, and payer frameworks drives ecosystem maturity and innovation. Firms align autoimmune strategies with value-based care, chronic disease management, and employer wellness goals. These trends are accelerating regional growth across North America's autoimmune disease infrastructure and therapeutic platforms.

Key players in the market

Some of the key players in Autoimmune Disease Therapeutics Market include AbbVie Inc., Johnson & Johnson Services Inc., Pfizer Inc., Amgen Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Sanofi S.A., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, UCB S.A., Biogen Inc., Gilead Sciences Inc., AstraZeneca PLC and Merck & Co., Inc.

Key Developments:

In June 2025, AbbVie announced a definitive agreement to acquire Capstan Therapeutics for up to $2.1 billion, and completed the transaction. Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) delivering mRNA encoding anti-CD19 CAR to CD8+ T cells. The acquisition added a potential first-in-class therapy for B cell-mediated autoimmune diseases, aiming for durable, drug-free remission.

In October 2023, Amgen completed the $27.8 billion acquisition of Horizon Therapeutics plc, gaining access to first-in-class therapies for rare autoimmune diseases. The deal added Tepezza (thyroid eye disease) and Krystexxa (chronic gout) to Amgen's portfolio, significantly expanding its reach in immunology and inflammation markets.

Drug Classes Covered:

• Immunosuppressants
• Anti-inflammatory Drugs
• Corticosteroids
• Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
• Biologics
• Biosimilars

Indications Covered:

• Rheumatoid Arthritis
• Psoriasis & Psoriatic Arthritis
• Inflammatory Bowel Disease (Crohn's Disease, Ulcerative Colitis)
• Systemic Lupus Erythematosus
• Multiple Sclerosis
• Type 1 Diabetes
• Ankylosing Spondylitis
• Other Indications

Route of Administrations Covered:

• Oral
• Injectable
• Intravenous

Distribution Channels Covered:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Specialty Clinics

End Users Covered:

• Hospitals
• Clinics
• Homecare Settings
• Research & Academic Institutes
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 End User Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Autoimmune Disease Therapeutics Market, By Drug Class

• 5.1 Introduction
• 5.2 Immunosuppressants
• 5.3 Anti-inflammatory Drugs
• 5.4 Corticosteroids
• 5.5 Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
• 5.6 Biologics
  • 5.6.1 TNF Inhibitors
  • 5.6.2 Interleukin Inhibitors
  • 5.6.3 B-cell and T-cell Modulators
• 5.7 Biosimilars

6 Global Autoimmune Disease Therapeutics Market, By Indication

• 6.1 Introduction
• 6.2 Rheumatoid Arthritis
• 6.3 Psoriasis & Psoriatic Arthritis
• 6.4 Inflammatory Bowel Disease (Crohn's Disease, Ulcerative Colitis)
• 6.5 Systemic Lupus Erythematosus
• 6.6 Multiple Sclerosis
• 6.7 Type 1 Diabetes
• 6.8 Ankylosing Spondylitis
• 6.9 Other Indications

7 Global Autoimmune Disease Therapeutics Market, By Route of Administration

• 7.1 Introduction
• 7.2 Oral
• 7.3 Injectable
• 7.4 Intravenous

8 Global Autoimmune Disease Therapeutics Market, By Distribution Channel

• 8.1 Introduction
• 8.2 Hospital Pharmacies
• 8.3 Retail Pharmacies
• 8.4 Online Pharmacies
• 8.5 Specialty Clinics

9 Global Autoimmune Disease Therapeutics Market, By End User

• 9.1 Introduction
• 9.2 Hospitals
• 9.3 Clinics
• 9.4 Homecare Settings
• 9.5 Research & Academic Institutes
• 9.6 Other End Users

10 Global Autoimmune Disease Therapeutics Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 AbbVie Inc.
• 12.2 Johnson & Johnson Services Inc.
• 12.3 Pfizer Inc.
• 12.4 Amgen Inc.
• 12.5 Novartis AG
• 12.6 F. Hoffmann-La Roche Ltd.
• 12.7 Bristol-Myers Squibb Company
• 12.8 Sanofi S.A.
• 12.9 Eli Lilly and Company
• 12.10 Takeda Pharmaceutical Company Limited
• 12.11 UCB S.A.
• 12.12 Biogen Inc.
• 12.13 Gilead Sciences Inc.
• 12.14 AstraZeneca PLC
• 12.15 Merck & Co., Inc.